Fig. 3 | Nature Communications

Fig. 3

From: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Fig. 3

Forest plot for performance on PFS of predictive risk score stratified by clinicopathological features based on the Cox models. P-values were calculated using the two-sided log-rank test. HR and 95% CIs were given and visually represented by the squares and error bars. ECOG Eastern Cooperative Oncology Cohort, ER estrogen receptor, PR progesterone receptor, HR hazard ratio, 95% CI 95% confidence interval

Back to article page